mpMRI靶向活检导致ISUP 2级前列腺癌过度诊断与分期迁移:事实还是虚构
基于前瞻性多机构数据库,纳入仅经靶向活检诊断为ISUP 2级前列腺癌的1293例患者,评估靶向穿刺是否导致根治性前列腺切除标本降级。仅33例(2.6%)出现降级,总肿瘤长度(OR 0.71)和经会阴穿刺途径(OR 0.38)与降级风险降低相关。
要点
- 仅靶向活检诊断ISUP 2级患者中,根治性前列腺切除标本降级率仅2.6%(33/1293)。
- 总肿瘤长度(mm)与降级风险降低相关(OR 0.71,95%CI 0.62-0.82,p<0.001)。
- 经会阴穿刺途径与降级风险降低相关(OR 0.38,95%CI 0.14-1.00,p=0.05)。
核心结论
- 仅经靶向活检诊断为ISUP 2级且器官局限的患者中,根治性前列腺切除标本降级比例低(2.6%),靶向活检导致过度诊断的推测需谨慎看待。
研究设计与样本
- 基于前瞻性维护的多机构数据库,识别仅经靶向活检诊断为ISUP 2级前列腺癌的1293例患者。
主要发现
- 患者诊断时中位年龄65(IQR 60-70)岁,中位PSA 6.8(IQR 5.0-9.6)ng/ml。
- 总体仅33例(2.6%)根治性前列腺切除标本出现降级。
- 降级患者更常经直肠穿刺、总肿瘤长度更短、最大穿刺针受累百分比更低、系统穿刺检出癌比例更低(均p≤0.03)。
- 总肿瘤长度(mm)与降级风险降低相关(OR 0.71,95%CI 0.62-0.82,p<0.001)。
- 经会阴穿刺途径与降级风险降低相关(OR 0.38,95%CI 0.14-1.00,p=0.05)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recently, the use of targeted biopsy has been subject to critics, as it has been speculated that targeted biopsy might lead to overdiagnosis of clinically significant prostate cancer (PCa). In this study, we tried to evaluate whether targeted sampling in patients with organ-confined disease and ISUP 2 disease was associated with downgrading of the prostatectomy specimen, hence, leading to an unnecessary treatment, in terms of radical surgery. We relied on a prospectively-maintained multi-institutional database and identified 1293 patients with ISUP 2 disease on targeted biopsy only. Median (IQR) patients' age at diagnosis was 65 (60, 70) years. Median PSA was 6.8 (5.0, 9.6) ng/ml. Overall, only 33 (2.6%) patients presented downgrading on their RP specimens. Patients who experienced downgrading were biopsied more frequently trans-rectally, had a lower total tumor length in mm and lower percentage of maximum core involvement and lower rates of cancer on systematic biopsy (all p ≤ 0.03). The strongest factors associated with reduced risk of downgrading were total tumor length, in mm, (OR: 0.71, 95% CI: 0.62,0.82, p < 0.001) and transperineal biopsy route (OR: 0.38, 95% CI: 0.14,1.00, p = 0.05).
引用
- Martini A, Touzani A, Mazzone E, et al. Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions. Prostate Cancer Prostatic Dis. 2022. PMID: 36209238. doi:10.1038/s41391-022-00606-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。